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Abstract
Background: Open AAA repair is associated with ischaemia-reperfusion injury where
systemic inflammation and endothelial dysfunction can lead to multiple organ injury
including acute lung injury. Oxidative stress plays a role that may be inhibited by
ascorbic acid.
Methods: A double blind, allocation concealed, randomized placebo-controlled trial
was performed to test the hypothesis that a single bolus dose (2g) of intra-operative
parenteral ascorbic acid would attenuate biomarkers of ischaemia-reperfusion injury
in patients undergoing elective open AAA repair.
Results: Thirty one patients completed the study; 18 received placebo and 13
ascorbic acid. Groups were comparable demographically. Open AAA repair caused
an increase in urinary Albumin:Creatinine Ratio (ACR) as well as plasma IL-6 and IL-8.
There was a decrease in exhaled breath pH and oxygenation. Lipid hydroperoxides
were significantly higher in the ascorbic acid group following open AAA repair. There
were no other differences between the ascorbic acid or placebo groups up to 4
hours after removal of the aortic clamping.
Conclusions: Open AAA repair caused an increase in markers of systemic endothelial
damage and systemic inflammation. Administration of 2g parenteral ascorbic acid
did not attenuate this response and with higher levels of lipid hydroperoxides post-
operatively a pro-oxidant effect could not be excluded.
Trial registration: ISRCTN27369400
Keywords: Ascorbic Acid; Ichaemia-Reperfusion injury; Abdominal aortic aneurysm;
Perioperative anaesthesia; Perioperative critical care
Background
Open Abdominal Aortic Aneurysm (AAA) repair necessitates the use of an aortic
cross-clamp which causes an ischaemia-reperfusion injury to remote tissues which can
lead to multiple organ dysfunction syndrome (MODS) including acute lung injury
(ALI) and death [1].
Ischaemia-reperfusion injury is associated with an increase in oxidative stress through
the accumulation of reactive oxygen species (ROS) which can up-regulate pro-
inflammatory pathways contributing to remote organ dysfunction [2,3]. Lipid peroxidation
is central in oxidative stress and can be measured using end products [4]. Ischaemia leads
to endothelial activation with increased expression of endothelial adhesion molecules [5].
© 2015 Duffy et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
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Reperfusion enhances this response and is associated with up-regulation of plasma cyto-
kines [6] and increased leucocyte interaction [7]. Increased urinary albumin:creatinine ra-
tio (ACR) has been associated with impaired endothelial-dependent vasodilation [8], a
surrogate measure of endothelial dysfunction [9]. There is evidence of systemic endothe-
lial dysfunction as measured by urinary albumin:creatinine ratio (ACR) in patients under-
going open AAA repair [10] correlating with outcome from ALI in this setting [11,12]. In
patients undergoing open AAA repair a rise in ACR measured 4 hours following induc-
tion of anaesthesia predicted those at risk of post-operative pulmonary dysfunction [13].
Pulse Wave Analysis (PWA) provides a bedside measure of systemic endothelial func-
tion and has been shown to independently predict mortality in the critically ill [14]. Pul-
monary dead-space fraction is increased in the acute respiratory distress syndrome
(ARDS) and may reflect the extent of pulmonary endothelial dysfunction [15].
Ascorbic acid can act as a reactive oxygen species (ROS) scavenger [16,17]. Low
ascorbic acid levels have been described in humans subjected to ischaemia-reperfusion
injury during cardiac surgery [18,19] and are associated with acute inflammation [20]. As-
corbic acid attenuates endothelial dysfunction in animal models of acute lung injury (ALI)
[21] a condition characterized by uncontrolled inflammation [22]. Ascorbic acid can im-
prove endothelial function [23] by inhibiting apoptosis [24], and preserving endothelial
barrier function [25]. As a scavenger it reduces oxidative uncoupling of endothelial nitric
oxide synthase (eNOS) leading to further ROS production [26,27]. The hypothesis in this
study was that an intra-operative bolus dose (2g) of parenteral ascorbic acid may attenuate
markers of oxidative stress, inflammation and endothelial dysfunction caused by open
AAA repair.
Methods
This was a single centre, double blind allocation concealed, randomized placebo-
controlled trial. The protocol was approved by the local institution, the UK Medicines
and Healthcare products Regulatory Agency and the regional ethics committee. Written
informed consent was obtained from each participant prior to study commencement. The
trial is registered with www.isrctn.com (ISRCTN27369400).
The study was performed at the Royal Victoria Hospital, Belfast, a tertiary care teach-
ing hospital. Adults undergoing elective open AAA repair were eligible for enrollment.
Exclusion criteria were age less than 18 years old, a history of hyperoxaluria or glucose-
6-phosphate dehydrogenase deficiency, prior antioxidant therapy, known allergy to as-
corbic acid or to anaesthetic agents specified in anaesthetic protocol, participation in
another intervention trial within 30 days or a lack of consent.
Patients were randomly assigned to receive intraoperative intravenous ascorbic acid 2 g
in 250 ml 0.9% saline or 250 ml 0.9% saline placebo over 15 minutes following induction
of anaesthesia. Block randomization was performed by an independent statistician. The
randomization assignments were concealed in sealed, tamper-proof envelopes that were
opened sequentially by an independent pharmacist. When an eligible subject was re-
cruited, the pharmacist allocated the subject to the designated treatment group,
maintaining blinding. Ascorbic acid and 0.9% saline were prepared by the independ-
ent pharmacist and had an identical appearance. All staff and participants were
blinded to treatment allocation.
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Data collection
Baseline demographic data were collected including medical history. All participants
underwent transperitoneal open AAA repair via midline laparotomy. Anaesthesia was
provided via a standardized technique.
A summary of events and measurements performed is shown in Figure 1.
Measurements
Plasma and serum samples were obtained from arterial blood samples taken from the
indwelling arterial catheter. Blood samples were centrifuged at 2000 rpm for 10 mi-
nutes at 10°C and then samples were frozen at -80°C until analysis. Urine samples were
collected and frozen at -80°C until analysis.
Plasma Von Willebrand Factor (vWF) level was measured by ELISA as previously de-
scribed [11]. Soluble forms of Intercellular adhesion molecule (sICAM)-1, vascular cell
adhesion molecule (sVCAM)-1, endothelial (sE)-Selectin and platelet (sP)-Selectin were
measured using a Fluorokine® MAP multiplex kit (R&D Systems, Minneapolis, MN,
USA) with a BioRad BioPlex™ analyser (Luminex Corp., Austin, TX, USA). Interleukins
IL-6 and IL-8 were measured using a cytometric bead array (R&D Systems, Abingdon,
UK) as previously described [28]. Serum highly sensitive C Reactive Protein (hsCRP)
analysis was performed using the Quantex CRP ultra sensitive quantitative system (ILab
Chemistry Systems, Instrumentation Laboratory Company, Lexington, Mass). Serum
aqueous phase lipid hydroperoxides were measured using the ferrous iron/xylenol or-
ange (FOX) assay as previously described [29]. Plasma 8-iso-Prostaglandin F2α was
measured using a direct enzyme immunoassay kit (Assay Designs Inc., Ann Arobor,
Michigan, USA) with a BioRad BioPlex™ analyser (Luminex Corp., Austin, TX, USA).
To measure plasma ascorbic acid, plasma was mixed with 5% meta-phosphoric acid
(MPA) to stabilise ascorbic acid and then measured on a Cobas FARA centrifugal ana-
lyser with a fluorescent attachment according to Vuilleumier & Keck [30]. To deter-
mine urinary ACR, albumin was measured in urine using a commercially available
immunoturbidimetric assay containing antibody specific for human albumin (Randox
Laboratories Ltd. Crumlin, Co. Antrim, UK). Creatinine was measured using a modified
Jaffe method as previously described (Roche Diagnostics, IN, USA) [31].
PWA was used to assess systemic endothelial function as previously described [14].
This was performed with the SphygmoCor Mx System (AtCor Medical, Sydney,
Australia). An indwelling 20G radial arterial catheter was used to obtain a calibrated
peripheral arterial pressure waveform. The central aortic waveform was derived from
the peripheral arterial waveform using a validated transfer function [32,33]. Aortic
Pre-operative Intra-operative Post-operative
Baseline PWA
Blood & Urine 
Anesthesia 
Induction
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Figure 1 Summary of study period events and measurements. PWA – Pulse Wave Analysis, PDSF –
Pulmonary Dead-Space Fraction, PFR – PaO2:FiO2 Ratio, EBC – Exhaled Breath Condensate.
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augmentation is defined as the difference between the first systolic peak (caused by left
ventricular contraction) and second systolic peak (caused by wave reflection) and the
augmentation index (AIx) is this difference expressed as a percentage of the central
pulse pressure. AIx is calculated and corrected to a heart rate to 75 beats/min. The AIx
following nebulised salbutamol 2.5mg measures endothelium dependent vasodilation
(EDV) [34].
Pulmonary Dead-Space Fraction (Vd/Vt) was measured using volumetric capnography
utilizing the NICO2 Monitor (Philips Respironics UK Ltd., Tangmere, UK) to calculate
the partial pressure of expired CO2. This is then used in the Enghoff modification of the
Bohr equation [35]. This method has been validated in a cohort of patients with acute
lung injury [36].
Exhaled Breath Condensate (EBC) pH as a measure of alveolar neutrophilic inflam-
mation was measured in EBC collected using an RTube™ (Respiratory Research, Austin,
TX, USA) as previously described [37]. Exhaled breath condensate pH was measured
using an Orion 9803BN micro pH electrode and digital pH meter (Thermo Scientific,
Waltham, MA, USA) immediately after collection.
Statistics
Proportions were used as descriptive statistics for categorical variables. Mean (standard
deviation) or median (interquartile range) were used as appropriate after testing for
normality with the Kolmogorov-Smirnov test. Between group categorical variables were
compared using Fishers exact test and continuous variables with an unpaired Student’s
t-test or Mann-Whitney U test as appropriate. Comparison of variables before and after
open AAA repair was made using a paired Student’s t-test or Wilcoxon matched pairs
test as appropriate. Statistical analysis was performed and graphs generated using Prism
5 for Mac OS X, version 5.0b (GraphPad Software Inc.). A P value of <0.05 was consid-
ered significant.
Power calculation
The sample size calculation was determined using data from a previous study examin-
ing plasma vWF concentration in elective open AAA repair patients [12]. Based on
these data, mean (standard deviation) vWF concentrations of 175(56) and 125(40) U/dl
were assumed for patients receiving placebo and ascorbic acid respectively. On this
basis 31 patients were required to complete the study. On the basis of assumed unequal
variance between the groups, 18 patients were allocated to receive placebo and 13 to
receive ascorbic acid. This provided 80% power to detect a statistical difference if the
true difference was as suggested above. This calculation assumed that a two-tailed t-test
at a 5% significance level was applied.
Results
Forty three patients were screened over an 18 month period. Twelve patients were ex-
cluded. Thirty-one participants received study drug, completed the study and were in-
cluded in the analysis. Thirteen patients received ascorbic acid and 18 received placebo
(Figure 2).
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Baseline characteristics were similar in both groups. The duration of ischaemic injury
caused by the aortic clamp was similar between groups (Table 1). Mean arterial pres-
sure fell intra-operatively from 101 (17) mmHg to 85 (15) mmHg in the ascorbic acid
group (p = 0.03) and from 101 (16) mmHg to 82 (15) mmHg in the placebo group
(p < 0.001) but there were no differences between groups either pre- or post-
operatively. Ascorbic acid levels measured four hours following removal of the aortic
clamp were higher in the ascorbic acid group compared to placebo (104.4 (84.8, 132.7)
μmoll-1 vs 18.2 (6.2, 34.5) μmoll-1, p < 0.001).
Effects of ascorbic acid on endothelial function
Plasma VWF levels were similar between groups both before and after open AAA repair.
Similarly there were no differences in EDV between groups either pre- or post-operatively
(Table 2). Urinary ACR was significantly higher in both the placebo (p < 0.001) and ascor-
bic acid (p = 0.01) groups after AAA repair, however there were no differences between
the groups (Figure 3). There were no significant changes in pulmonary deadspace follow-
ing open AAA repair (Table 2).
Effects of ascorbic acid on soluble adhesion molecules
Plasma sICAM-1 fell within both the placebo (p < 0.001) and ascorbic acid (p = 0.005)
groups after open AAA repair, There was no difference between placebo and ascorbic
Assessed for eligibility
n=43
Participants randomised 
n=31
Excluded n=12  
Change in surgical plan n=4
Pharmacy unable to supply drug n=1
Research fellow unavailable n=1
No consent n=5
No radial artery access n=1
Allocated to control group
n=18
Allocated to intervention
n=13
Lost to follow up
n=0
Lost to follow up
n=0
Analysed n=18 Analysed n=13
Figure 2 Consort diagram of study recruitment.
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acid groups pre-operatively (p = 0.1) however plasma sICAM-1 was higher in the ascor-
bic acid group post-operatively (p = 0.03 vs placebo, Figure 4A). Plasma sVCAM-1 was
similar pre and post open AAA repair in both groups and there was no difference
between groups (Figure 4B). Plasma sE-Selectin fell post-operatively within both the
Table 1 Demographic, historical and pre-operative physiological parameters
Placebo group Ascorbate group
n = 18 n = 13
Mean (SD), Median
(IQR) or n (%)
Mean (SD), Median
(IQR) or n (%)
Demographics
Age (years) 70.4 (7.4) 73.2 (5.9)
Height (m) 1.71 (0.09) 1.71 (0.05)
Weight (kg) 77.1 (11.1) 78.2 (7.7)
BMI (kgm−2) 26.4 (3.3) 26.8 (2.8)
Gender (% male) 17 (94%) 11 (85%)
Past medical history
IHD 8 (44%) 4 (31%)
Atrial Fibrillation 0 (0%) 2 (15%)
Hypertension 16 (89%) 12 (92%)
Cerebrovascular Disease 1 (6%) 1 (8%)
Cardiovascular risk factors
Smoking 4 (22%) 5 (38%)
Hypercholesterolaemia 10 (56%) 6 (46%)
Hypertension 16 (89%) 12 (92%)
Diabetes 1 (6%) 0 (0%)
Drug history
Statin 12 (67%) 9 (69%)
ACE Inhibitors 5 (28%) 3 (23%)
β Blockers 7 (39%) 6 (46%)
Diuretics 2 (11%) 3 (23%)
Anticoagulants 5 (28%) 5 (38%)
Baseline physiological parameters
Respiratory Rate (min−1) 14 (12,15) 12 (12,15)
Temperature (°C) 36.6 (0.33) 36.8 (0.38)
Heart Rate (min−1) 63 (10.3) 60 (13.7)
Peripheral SBP (mmHg) 145.2 (24.9) 150.5 (29.6)
Peripheral DBP (mmHg) 77 (12.4) 76 (11.7)
Haematological and biochemical indices
Haemoglobin (gdl−1) 13.7 (1.2) 13.7 (1.1)
Leucocyte Count (x109ml−1) 7.3 (1.7) 7.3 (1.8)
Platelet Count (x109ml−1) 201 (54) 211 (64)
Urea (mmoll−1) 7.8 (2.1) 6.7 (1.8)
Creatinine (μmoll−1) 96 (31) 101 (30)
Surgical details
Ischaemic Time (mins) 60.5 (16.9) 64.6 (17.6)
SD, Standard Deviation, IQR, Interquartile Range, BMI, Body Mass Index, SBP, Systolic Blood Pressure, DBP, Diastolic Blood
Pressure, IHD, Ischaemic Heart Disease, ACE, Angiotensin Converting Enzyme.
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placebo (p < 0.001) and ascorbic acid (p = 0.002) groups, although there was no differ-
ence between the groups (Figure 4C). Plasma sP-Selectin fell post-operatively within
the placebo (p = 0.0001) but not the ascorbic acid (p = 0.41) groups, although there was
no difference between the groups (Figure 4D).
Effects of ascorbic acid on systemic and pulmonary markers of inflammation
Plasma CRP was similar pre and post open AAA repair in both groups and there was
no difference between groups (Table 2). Plasma IL-6 increased during the study period
in the placebo (p < 0.001) and ascorbic acid (p < 0.001) groups although there was no
difference between the groups (Figure 5A). Similarly plasma IL-8 also increased signifi-
cantly in both placebo (p < 0.001) and ascorbic acid (p < 0.001) groups but again there
was no difference between the groups (Figure 5B).
Table 2 Comparison of biomarkers in ascorbic acid and placebo groups pre- and
post-operatively
Pre operative parameters Post operative parameters
Placebo
group
Ascorbate
group
p-value Placebo
group
Ascorbate
group
p-value
n = 18 n = 13 n = 18 n = 13
Mean (SD), Mean (SD), Mean (SD), Mean (SD),
Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Endothelial function
vWF (% Control) 141 (61) 139 (60) 0.92 158 (78) 169 (65) 0.68
EDV (%) 3.5 (1.8, 5.3) 3.0 (1.5, 5.5) 0.42 6.0 (2.5, 8.5) 4.0 (2.0, 6.0) 0.32
Vd/Vt 0.56 (0.06) 0.54 (0.05) 0.53 0.56 (0.06) 0.54 (0.06) 0.74
Systemic and pulmonary inflammatory mediators
Serum hsCRP (mgL−1) 2.14 (0.97, 5.75) 1.83 (1.15, 4.49) 0.95 2.85 (1.45, 4.63) 1.96 (1.13, 4.23) 0.27
Arterial pH 7.38 (0.04) 7.40 (0.05) 0.43 7.32 (0.08) 7.29 (0.06) 0.20
Pulmonary function
PaO2:FiO2 ratio (kPa) 59.6 (47.8, 81.1) 59.6 (46.5, 97.7) 0.44 45.3 (28.3, 49.4) 42.5 (32.7, 51.4) 0.79
SD, Standard Deviation, IQR, Interquartile Range, EDV, Endothelium-dependent vasodilatation, vWF, von Willebrand
Factor, Vd/Vt, Pulmonary Deadspace Fraction, EBC, Exhaled Breath Condensate, CRP, C Reactive Protein.
Figure 3 There was a significant increase in urinary ACR in the placebo group from 0.99(0.58,3.9) to
15.6(6.0,30.9)mg/mmol and in the treatment group from 0.77(0.5,2.6) to 8.1(3.1,26.3)mg/mmol. There were
no differences between groups either pre- (p = 0.56) or postoperatively (p = 0.37).
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EBC pH decreased in both the placebo (p = 0.008) and ascorbic acid (p = 0.002) groups
post-operatively although there was no difference between the groups (Figure 6). Systemic
arterial pH also decreased in both the placebo (p < 0.001) and ascorbic acid (p = 0.005)
groups post-operatively although there was no difference between the groups (Table 2).
There was no significant correlation in the change in systemic arterial pH and EBC pH in
either the placebo (p = 0.52, r2 = 0.03) or ascorbic acid (p = 0.23, r2 = 0.13) groups.
Effects of ascorbic acid on systemic oxidative stress
Plasma lipid hydroperoxides decreased in the placebo group (p = 0.002) but not in the
ascorbic acid group (p = 0.38). Furthermore post-operative lipid hydroperoxides were sig-
nificantly higher in the ascorbic acid group (p < 0.001, Figure 7A). Plasma 8-isoprostane
was similar pre and post open AAA repair in both groups and there was no difference
between groups (Figure 7B).
Effects of ascorbic acid on pulmonary function and clinical outcomes
The PaO2:FiO2 ratio fell significantly in both placebo (p = 0.002) and ascorbic acid
(p < 0.001) groups although there was no difference between groups (Figure 8).
Post-operative infections were diagnosed in 3 (17%) of the placebo group and in 2
(8%) of the ascorbate group (p = 0.62). Only 3 patients in each group required post-
operative invasive ventilation and the duration of ventilation was similar between
groups (p = 0.77). The duration of stay in critical care was similar between the placebo
Figure 4 Endothelial adhesion molecules. (A) Plasma sICAM-1 levels decreased in the placebo group from
245(50) to 162(51) ng/ml and in the ascorbic acid group from 287(79) to 204(52) ng/ml after AAA repair
and post-operatively were significantly lower in the placebo group compared to ascorbic acid (p = 0.03).
(B) Plasma sVCAM-1 levels did not change after AAA repair. In the placebo group the preoperative level
was 1132(427) ng/ml and post-operatively 998(484)ng/ml (p = 0.3). In the ascorbic acid group the
preoperative level was 1223(471)ng/ml and postoperatively 1088(505)ng/ml (p = 0.4). There were no
differences between groups and any time point. (C) sE-Selectin levels decreased in the placebo group from
35(12) to 25(13)ng/ml (p < 0.001) and in the ascorbic acid group from 37(11) to 26(8)ng/ml (p = 0.002) after
AAA repair. There were no differences between groups. (D) sP-Selectin levels decreased in the placebo
group from 82(52,88) to 59(52,75)ng/ml (p = 0.001) after AAA repair. In the ascorbic acid group the levels
were similar pre- and post-operatively (79(70,95) vs. 69(59,82)ng/ml) (p = 0.4).
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and ascorbic acid groups (2.9 (3.5) days versus 2.3 (3.2) days, p = 0.64). Similarly there
was no difference in hospital stay (10.2 (4.8) versus 8.8 (2.6) days, p = 0.37). There was
one post-operative fatality in the placebo group. No serious adverse reactions related to
the study drug occurred.
Discussion
We have found that open AAA repair caused significant changes in markers of sys-
temic endothelial dysfunction as well as an increase in systemic and pulmonary inflam-
mation, and a reduction in a marker of pulmonary function. However ascorbic acid
therapy did not attenuate changes in these biomarkers following open AAA repair.
Our findings are in keeping with previous data showing increased urinary ACR and
inflammation and with a decrease in PaO2:FiO2 ratio following open AAA repair
[12,38]. In contrast to these findings however we did not see an increased serum CRP
or increased plasma vWF. An increasing proportion of participants now receive treat-
ment for co-morbid conditions such as statins. Statins have anti-inflammatory effects
[28,39] and may modulate endothelial function modifying responses to open AAA sur-
gery. We found no increase in pulmonary dead space fraction. It is possible that the in-
jury was not sufficient to induce pulmonary endothelial dysfunction or that the time to
post operative assessment was of insufficient duration. As part of the standardized an-
aesthetic protocol, maintenance was with sevoflurane which has been shown to protect
the endothelium from ischaemia-reperfusion injury [40] and might have further attenu-
ated any potential pulmonary endothelial injury.
Figure 5 (A) IL-6 increased in the placebo group from 4.9(4.9,5.0) to 41.8(33.5,77.4) pg/ml (p < 0.001) and in
the ascorbic acid group from 4.9(4.9,5.0) to 29.0(13.3,52.3) pg/ml (p < 0.001) after AAA repair. (B) IL-8 levels
increased in the placebo group from 9.5(5.6,15.6) to 33.6(18.3,38.6) pg/ml (p < 0.001) and in the ascorbic
acid group from 9.8(3.7,13.7) to 20.7(14.8,52.9) pg/ml (p < 0.001) after open AAA repair. There was no
difference between groups at any time-point for either of these inflammatory mediators.
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The fall in EBC pH as a marker of alveolar neutrophilic inflammation was an inter-
esting finding. This was associated with a decrease in the PaO2:FiO2 ratio. The fall in
EBC pH in this study may reflect pulmonary inflammation given that there was no cor-
relation found with this decrease and changes in systemic pH.
Ischaemia-reperfusion injury has been used to provoke acute lung injury (ALI) in ani-
mal models [41]. The obligate ischaemia-reperfusion injury of open AAA repair is asso-
ciated with post operative pulmonary dysfunction [42]. A recent observational study
Figure 6 EBC pH decreased in the placebo group from 7.38(0.04) to 7.32(0.08) (p = 0.008) after open AAA
repair. In the ascorbic acid group the EBC pH fell from 7.40(0.05) to 7.29(0.06) (p = 0.002) post-operatively.
The pre- and post-operative levels were similar between groups (Table 2).
Figure 7 Oxidative stress markers. (A) Lipid hydroperoxide decreased in the placebo group from 0.8(0.7,0.9)
to 0.5(0.4,0.5)μmol/l (p = 0.002) after AAA repair. In the ascorbic acid group the preoperative level 0.6(0.5,0.7)μmol/l
did not change and postoperatively was 0.6(0.6,0.8)μmol/l (p = 0.4). Post-operatively lipid hydroperoxide
levels were significantly higher in the ascorbic acid group compared with placebo (p < 0.001). (B) Plasma
8-isoprostane levels did not change after AAA repair in either group and there was no difference between
groups at any time-point. In the placebo group the preoperative level 18.4(15.9,24.8)ng/ml did not change after
AAA repair being 20.4(18.6,25.1)ng/ml (p = 0.3). In the ascorbic acid group the preoperative level 19.1(16.6,23.7)ng/ml
did not change and postoperatively was 19.7(18.2,23.2)ng/ml (p = 0.6). There was no difference between groups at
any time point.
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found that post-operative respiratory failure was associated with increased mortality
[43]. Reflecting findings in ALI, we have shown open AAA repair is associated with local
alveolar inflammation as well as systemic endothelial dysfunction and inflammation. Ele-
vated plasma IL-6 and -8 levels are predictive of outcome in patients with ALI [44]. As a
marker of systemic vascular permeability, urinary ACR has been shown to have an inverse
relationship with PaO2:FiO2 ratio in a cohort of trauma patients [45]. These findings sup-
port the use of open AAA repair as a human model of ALI induced by systemic inflam-
mation. However, in the present study mediators implicated in ALI such as vWF [11]
were not elevated. It is possible that endothelial injury was not caused to a measurable
level. In a murine model of ALI the administration of parenteral ascorbic acid (200 mg/
ml) 30 minutes after a septic insult attenuated the inflammatory response and was associ-
ated with improved survival, pulmonary function and coagulation [21]. In this study
Fisher and colleagues suggested that the protective effects of ascorbic acid are due to its
pleotropic actions on multiple pathways and it is possible in the current study, a lack of
benefit may be related to the limitations in biomarkers used.
We investigated a single 2 g bolus of intravenous ascorbic acid following induction of
anaesthesia in this study. This dose was informed by previous research where pre-
treatment with 2 g ascorbic acid was found to modulate the adverse haemodynamic
effects of experimentally induced hyperglycaemia [46]. In addition ascorbic acid (2 g)
has been shown to prevent hyperglycaemia-induced endothelial dysfunction in healthy
human volunteers [47].
In the present study a decrease in plasma adhesion molecules was found. Haemodilu-
tion as part of intra-operative management could be potential mechanism for the
reduction in soluble adhesion molecules as well as the lack of increase in serum hsCRP.
However, as plasma IL-6 and IL-8 both increased, haemodilution is less likely. Co-
morbid treatment may also have influenced adhesion molecules expression. Both
statins and β blockers may modify adhesion molecules expression. Human coronary
endothelial cells treated with nebivolol in vitro have a decrease in VCAM-1, ICAM-1,
E- and P-Selectin expression [48]. Interestingly in another study of open AAA repair
there was a non-significant fall in both ICAM-1 and VCAM-1 [49]. This has been mir-
rored in an in vitro study of human aortic endothelial cells which showed exposure of
these cells to hypoxia and subsequent reoxygenation did not upregulate surface expres-
sion or shedding of adhesion molecules [50].
Figure 8 The PaO2:FiO2 ratio decreased in the placebo group from 447 (398, 608) to 340 (212, 370) mmHg
(p = 0.002) and in the ascorbic acid group from 447 (349, 733) to 319 (245, 385) mmHg (p = 0.002) after AAA
repair. There were no differences demonstrated between groups (Table 2).
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There was no increase in markers of oxidative stress in the placebo group unlike in
other studies. Prosaglandin F2α is increased both on hospital arrival and during the
perioperative period in patients with ruptured AAA repair [51]. Malondialdehyde, an-
other marker of oxidative damage was increased at one and 24 hours post open AAA
repair [52]. In a recent small observational study derivatives of reactive oxygen metabo-
lites were used to define post-operative oxidative stress in patients undergoing aortic
surgery. This showed that in those having open AAA repair this marker was no differ-
ent at 24 hours after surgery, but was significantly elevated 1 week later [53]. This study
had an earlier sampling time, older cohort of patients and aortic clamp times contribut-
ing to the different data between studies.
Ascorbic acid did not improve markers of endothelial function or attenuate the
inflammatory response markers in this study. In previous research pretreatment with
2000mg parenteral ascorbic acid prevented arterial stiffness secondary to induced
hyperglycaemia in healthy male volunteers [23]. In a study of 37 critically ill patients
with burns the use of high dose ascorbic acid (66 mg/kg/hr) for 24 hours reduced fluid
requirements, wound oedema, and severity of pulmonary dysfunction [25]. In a double-
blind randomized placebo-controlled trial of 216 critically ill patients, enteral ascorbic
acid (500 mg/day) and tocopherol (400 IU/day) was associated with a decrease in 8-
isoprostane. The anti-oxidant treated group had improved 28-day mortality and more
ventilator free days [54]. We found lipid hydroperoxides were increased with ascorbic
acid. This increase in lipid peroxides was not seen in plasma 8-isoprostanes, another
measure of oxidative stress. Lipid hydroperoxides can be affected by dietary factors not
accounted for in the current study. Isoprostane levels however, are not affected by diet
[55] and may be a better measure of oxidative stress [56]. Previous studies utilizing the
FOX assay have indicated its lack of specificity for hydroperoxides [57]. However, in
keeping with our findings, Bailey at al found 2000 mg ascorbic acid orally two hours
before operation in patients undergoing major vascular surgery increased both lipid
peroxides and plasma IL-6 [58]. Possible reasons for increased oxidative stress markers
in this current study may relate to the timing of sampling and range of ischaemic times.
It is possible that at the dose used in this study, ascorbic acid acted as a pro-oxidant
with no beneficial effects on either the endothelium or measured mediators of
inflammation.
There are numerous limitations in this study. The patient cohort was small increasing
the risk of a type 2 error. Within the participants neither aneurysm size or anatomical
location were described. Duration of aortic clamping was recorded but the position was
not noted. Although the surgical approach and anaesthetic technique was standardized
the quantities of transfused blood products and fluids were not compared. Similarly the
need for cardiovascular support was not quantified. These confounding factors may
have had a consequence on the resultant endothelial injury. Having taken measure-
ments using a limited number of biomarkers of organ dysfunction up to only 4 hours
following aortic clamping may increase the risk of a type 1 error.
Conclusion
In conclusion, open AAA repair caused increased markers of systemic endothelial dys-
function and inflammation with an associated fall in oxygenation. These findings
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support the use of open AAA repair as a human model of ALI induced by systemic in-
flammation. Ascorbic acid administration did not improve the measured biomarkers
and limited functional parameters observed.
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